Medicinal composition

4-6. (canceled)

A kit which comprises (a) a first component containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, and
• (b) a second component containing at least one α1-adrenoceptor antagonist.

10-12. (canceled)

3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):

• or a pharmaceutically acceptable salt thereof.

(canceled)

A pharmaceutical composition which comprises, as an active ingredient, 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):

• or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.

A method for treating bladder irritative symptoms accompanied by benign prostatic hyperplasia, which comprises administering (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, and (b) an α1-adrenoceptor antagonist, which said (a) and (b) may be administered together or separately at an interval.